The protective effect of ulinastatin combined with Xuebijing on myocardial injuries in patients with severe pneumonia.

OBJECTIVE

To explore the protective effect of ulinastatin combined with Xuebijing on myocardial injuries in patients with severe pneumonia.

METHODS

The clinical data of 86 patients with severe pneumonia treated in our hospital were analyzed retrospectively. According to the treatment method each patient was administered, they were divided into a control group (43 cases, routine treatment + Xuebijing) and an observation group (43 cases, routine treatment + Xuebijing + ulinastatin). All the patients were treated for 2 weeks. The clinical efficacy, the inflammatory factor levels (TNF-α, C-reactive protein (CRP), and procalcitonin (PCT)), the myocardial index levels (creatine kinase-myocardial band (CK-MB), lactic dehydrogenase (LDH), α-hydroxybutyrate dehydrogenase (α-HBDE), N-terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac troponin I (cTn I)), the blood gas index levels (arterial partial pressure of oxygen (PaO2), oxygen saturation (SaO2), and oxygenation index (OI)), the coagulation functions (prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FIB)) and the acute physiology and chronic health evaluation (APACHE-II) scores were compared between the two groups.

RESULTS

After the treatment, the total effective rate in the observation group was higher than it was in the control group (P<0.05). After the treatment, the serum TNF-α, CRP, PCT, CK-MB, LDH, α-HBDE, NT-proBNP, and cTnI levels and the APACHE-II scores were decreased in the two groups, and they were even lower in the observation group (all P<0.05). The PaO2, SaO2, and OI levels were increased in the two groups, and they were higher in the observation group (all P<0.05). Compared with before the treatment, the patients' PT and APTT levels in both groups were prolonged after the treatment, and the observation group was longer than the control group. The plasma FIB levels were decreased in both groups, and they were lower in the observation group than in the control group (P<0.05).

CONCLUSION

Ulinastatin combined with Xuebijing can significantly alleviate pulmonary inflammation, improve the blood gas, and protect the damaged myocardia in patients with severe pneumonia.